Opportunity Information: Apply for W81XWH 21 OCRP CTRA
The CDMRP Ovarian Cancer Clinical Translational Research Award (CTRA) is a Department of Defense funding opportunity run through the Ovarian Cancer Research Program (OCRP) and administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed specifically to move promising ovarian cancer insights closer to real-world patient impact by supporting translational, clinically anchored research rather than basic laboratory or animal work. The emphasis is on work that can meaningfully inform patient care, treatment decisions, and clinical trial strategy by generating or validating clinically relevant evidence.
At its core, this award supports correlative studies linked to a clinical trial. In practice, that means the research must be associated with a planned, ongoing, or completed human clinical trial that is funded through other sources, since the award is not meant to pay for the operational costs of running the trial itself (for example, routine trial management, enrollment operations, or standard clinical procedures). Instead, the award targets the translational add-ons that often determine whether a trial truly advances the field: biomarker studies, analyses of patient specimens, tumor profiling, immune monitoring, molecular characterization, response and resistance investigations, and other human-based studies that help explain why a therapy works, for whom it works, and under what conditions.
The program is looking for translational research that addresses high-impact problems or clear unmet needs in ovarian cancer. Applications aligned with an OCRP priority area are especially encouraged, with a notable emphasis on precision medicine and computational approaches. The goal in this priority is to identify patient- and tumor-specific characteristics and predictive biomarkers, and to do so across diverse groups, so that patient care can be better tailored and outcomes can be improved. This highlights an interest in work that leverages modern analytic strategies (such as integrative multi-omics, machine learning, or other computational methods) to connect individual tumor biology with clinically actionable predictions, while also paying attention to diversity and representativeness in the studied populations.
While the award is centered on correlative science, it also explicitly encourages projects that develop clinical endpoints for clinical trials. This can include efforts to refine, validate, or propose endpoints that better capture patient benefit, biological activity, or early signals of response, particularly when standard endpoints are not sufficient or are slow to read out. The intent is to strengthen the clinical trial ecosystem in ovarian cancer by improving how trials measure meaningful outcomes and how they translate biological findings into decisions.
A key requirement is that applicants must be able to show the necessary human resources are truly available and accessible. This includes documenting access to the relevant human subject population and/or appropriate biospecimens and human-based resources needed to perform the proposed analyses. In other words, reviewers will expect credible evidence that the study can be executed as proposed, including the ability to obtain samples, clinical data, and follow-up information in a timely and compliant way.
The application must also include a detailed statistical analysis plan, including a power analysis tied to sample size projections. This is not a superficial requirement: the proposal needs to show that the planned number of participants or specimens is sufficient to detect meaningful effects and support interpretable conclusions. The program is signaling that it wants studies designed to produce clear, actionable outcomes rather than exploratory work that is underpowered or unlikely to provide definitive answers.
Finally, the scope is strictly human-centered: preclinical animal studies are not allowed under this mechanism. The opportunity is positioned firmly in the clinical-translational space, focusing on research that directly leverages human trial contexts, human samples, and clinically relevant endpoints to accelerate progress against ovarian cancer.
Administrative details from the source information include the funding opportunity number W81XWH-21-OCRP-CTRA, categorized as discretionary funding, with awards made as grants and/or cooperative agreements under the Department of Defense (Department of the Army, USAMRAA). The CFDA number listed is 12.420. Eligibility is described as unrestricted (open to any type of entity), subject to any additional clarifications in the full notice. The opportunity was created February 8, 2021, with an original closing date of July 8, 2021. The expected number of awards was 4, and the award ceiling is listed as 0 in the source data, which typically indicates that the ceiling was not specified in that summary field and would need to be confirmed in the full program announcement or budget guidance.Apply for W81XWH 21 OCRP CTRA
- The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "CDMRP Ovarian Cancer Clinical Translational Research Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
- This funding opportunity was created on Feb 08, 2021.
- Applicants must submit their applications by Jul 08, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the CDMRP Ovarian Cancer Clinical Translational Research Award (CTRA)?
The CDMRP Ovarian Cancer Clinical Translational Research Award (CTRA) is a Department of Defense funding opportunity within the Congressionally Directed Medical Research Programs (CDMRP). It sits under the Ovarian Cancer Research Program (OCRP) and is administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is intended to move promising ovarian cancer insights closer to patient impact by supporting translational, clinically anchored research rather than basic laboratory or animal studies.
What kind of research is this award designed to support?
This award supports translational research that can meaningfully inform patient care, treatment decisions, and clinical trial strategy by generating or validating clinically relevant evidence. The focus is on human-based studies connected to clinical trial contexts, such as biomarker and specimen analyses that help explain response, resistance, and which patients benefit from a therapy.
Does the CTRA fund clinical trials themselves?
No. The CTRA is intended to support correlative studies linked to a clinical trial, but it is not meant to cover the operational costs of running the clinical trial itself. Routine trial management, enrollment operations, and standard clinical procedures are specifically described as outside the purpose of this mechanism.
What does it mean that the project must be linked to a clinical trial?
The research must be associated with a planned, ongoing, or completed human clinical trial that is funded through other sources. The CTRA funds the translational "add-ons" (for example, correlative biomarker work, profiling, or immune monitoring) rather than the core clinical trial operations.
What are examples of "correlative studies" that fit this opportunity?
Examples described include biomarker studies, analyses of patient specimens, tumor profiling, immune monitoring, molecular characterization, and response/resistance investigations. In general, the work should use human samples and clinical data to explain outcomes and produce evidence that is clinically relevant and actionable.
Are basic laboratory studies or animal studies allowed?
No. The scope is described as strictly human-centered, and preclinical animal studies are not allowed under this mechanism.
What is the program's emphasis in ovarian cancer research?
The program emphasizes translational work that addresses high-impact problems or clear unmet needs in ovarian cancer. Applications aligned with an OCRP priority area are especially encouraged, with a notable emphasis on precision medicine and computational approaches.
How does precision medicine factor into the CTRA priorities?
The precision medicine priority described focuses on identifying patient- and tumor-specific characteristics and predictive biomarkers, including across diverse groups. The intention is to tailor patient care and improve outcomes by linking tumor biology to clinically actionable predictions.
Are computational approaches encouraged, and what might those include?
Yes. The information highlights an interest in modern analytic strategies such as integrative multi-omics, machine learning, or other computational methods that connect individual tumor biology with clinically actionable predictions, while also paying attention to diversity and representativeness in the studied populations.
Does this award support work on clinical trial endpoints?
Yes. In addition to correlative science, the opportunity explicitly encourages projects that develop clinical endpoints for clinical trials. This can include refining, validating, or proposing endpoints that better capture patient benefit, biological activity, or early signals of response, especially when standard endpoints are not sufficient or are slow to read out.
What are the requirements around access to patients, samples, and other human resources?
Applicants must be able to document that necessary human resources are available and accessible. This includes credible access to the relevant human subject population and/or appropriate biospecimens and other human-based resources needed to perform the proposed analyses, along with the ability to obtain samples, clinical data, and follow-up information in a timely and compliant way.
Is a statistical analysis plan required?
Yes. The application must include a detailed statistical analysis plan, including a power analysis tied to sample size projections. The intent is to ensure studies are designed to produce clear, interpretable, and actionable outcomes rather than being underpowered or purely exploratory.
What does the funding opportunity number W81XWH-21-OCRP-CTRA refer to?
W81XWH-21-OCRP-CTRA is the funding opportunity number listed for this award. It identifies the specific CDMRP/OCRP CTRA notice as presented in the source information.
Which agency administers this opportunity?
The opportunity is administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA) under the Department of Defense (Department of the Army), as part of the Ovarian Cancer Research Program (OCRP) within CDMRP.
What is the CFDA number for this opportunity?
The CFDA number listed in the source information is 12.420.
What type of funding mechanism is used for awards?
The source information describes the funding as discretionary, with awards made as grants and/or cooperative agreements.
Who is eligible to apply?
Eligibility is described as unrestricted (open to any type of entity), subject to any additional clarifications that may be provided in the full notice.
How many awards were expected?
The expected number of awards listed in the source information is 4.
What is the award ceiling (maximum award amount)?
The award ceiling is listed as 0 in the source data. This typically indicates that a ceiling was not specified in that summary field and would need to be confirmed in the full program announcement or budget guidance.
When was the opportunity created and when did it close?
The source information states the opportunity was created on February 8, 2021, with an original closing date of July 8, 2021.
What is the central goal of the CTRA in plain terms?
The central goal is to accelerate progress against ovarian cancer by funding human-centered, clinically anchored translational research that is connected to a clinical trial and can produce evidence that directly helps guide clinical decisions, trial strategy, and patient impact.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: DoD Gulf War Illness, New Investigator Award
Previous opportunity: OVW Fiscal Year 2021 Legal Assistance for Victims (LAV) Grant Program Solicitation
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 21 OCRP CTRA
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 21 OCRP CTRA) also looked into and applied for these:
| Funding Opportunity |
|---|
| CDMRP Ovarian Cancer Pilot Award Apply for W81XWH 21 OCRP PA Funding Number: W81XWH 21 OCRP PA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| CDMRP Ovarian Cancer, Ovarian Cancer Academy Award Apply for W81XWH 21 OCRP OCA Funding Number: W81XWH 21 OCRP OCA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| CDMRP Ovarian Cancer Proteogenomics Research Award Apply for W81XWH 21 OCRP PGRA Funding Number: W81XWH 21 OCRP PGRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Understanding the Rules of Life: Emergent Networks Apply for 21 560 Funding Number: 21 560 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Lung Cancer, Career Development Award Apply for W81XWH 21 LCRP CDA Funding Number: W81XWH 21 LCRP CDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Lung Cancer, Concept Award Apply for W81XWH 21 LCRP CA Funding Number: W81XWH 21 LCRP CA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Field Experiments for Chemical Control of Starry Stonewort (Nitellopsis obtusa) Apply for W81EWF 21 SOI 0009 Funding Number: W81EWF 21 SOI 0009 Agency: Department of Defense, Engineer Research and Development Center Category: Science and Technology and other Research and Development Funding Amount: $20,000 |
| Monitoring Ecological Parameters in the Forested Wetlands of Southern Florida Apply for W81EWF 21 SOI 0008 Funding Number: W81EWF 21 SOI 0008 Agency: Department of Defense, Engineer Research and Development Center Category: Science and Technology and other Research and Development Funding Amount: $415,787 |
| Stimulating Collaborative Advances Leveraging Expertise in the Mathematical and Scientific Foundations of Deep Learning Apply for 21 561 Funding Number: 21 561 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $1,200,000 |
| DoD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award Apply for W81XWH 21 ALSRP TIA Funding Number: W81XWH 21 ALSRP TIA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Amyotrophic Lateral Sclerosis, Therapeutic Development Award Apply for W81XWH 21 ALSRP TDA Funding Number: W81XWH 21 ALSRP TDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Amyotrophic Lateral Sclerosis, Therapeutic/Biomarker Pilot Trial Award Apply for W81XWH 21 ALSRP TBPTA Funding Number: W81XWH 21 ALSRP TBPTA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Amyotrophic Lateral Sclerosis, Clinical Development Award Apply for W81XWH 21 ALSRP CDA Funding Number: W81XWH 21 ALSRP CDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Developing Novel Engineering Design Methodologies for the Classroom, the Department of Defense, and Industry Apply for USAFA BAA 2021 CALL 0001 Funding Number: USAFA BAA 2021 CALL 0001 Agency: Department of Defense, Air Force Academy Category: Science and Technology and other Research and Development Funding Amount: $1,100,000 |
| Rehabilitation Engineering Research Centers (RERC) Program: RERC on Blindness and Low Vision Apply for HHS 2021 ACL NIDILRR REGE 0030 Funding Number: HHS 2021 ACL NIDILRR REGE 0030 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $925,000 |
| Rehabilitation Research and Training Center (RRTC) on Interventions to Promote Community Living Among People with Disabilities. Apply for HHS 2021 ACL NIDILRR RTCP 0028 Funding Number: HHS 2021 ACL NIDILRR RTCP 0028 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $875,000 |
| Public diplomacy grant program – Empowering communities through technology and education Apply for PAS MTY 2021 01 Funding Number: PAS MTY 2021 01 Agency: Department of State, U.S. Mission to Mexico Category: Science and Technology and other Research and Development Funding Amount: $25,000 |
| 2021 London Tech Bridge Research Opportunity Apply for N00014 21 S SN07 Funding Number: N00014 21 S SN07 Agency: Department of Defense, Office of Naval Research Category: Science and Technology and other Research and Development Funding Amount: $70,000 |
| Defense Medical Research and Development Program - En Route Care Award Apply for W81XWH 21 DMRDP ERCA Funding Number: W81XWH 21 DMRDP ERCA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Rehabilitation Engineering Research Centers (RERC) Program: RERC on Wireless Technologies Apply for HHS 2021 ACL NIDILRR REGE 0029 Funding Number: HHS 2021 ACL NIDILRR REGE 0029 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $925,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 21 OCRP CTRA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.